Europe Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.
The drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs and hormonal drugs such as gonadotropin-releasing hormone analogs (Gnrh Analogs), estrogen-progestin, selective progesterone receptor modulators (SPRMs) or progestin, aromatase inhibitors, and gonadotropin-releasing hormone antagonist, among others. Some of these drugs are used to reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.
The demand for adenomyosis drugs has increased more in developed countries. These countries had reimbursement policies for treatment along with the high prevalence of the disease and increasing healthcare expenditure. The market will grow in the forecasted period due to the exploration of emerging markets and increasing support of private and government agencies for treatment.
Europe adenomyosis drugs market report provides details of market share, new developments, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in ma
rket regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.
Europe adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe adenomyosis drugs market will grow at a CAGR of 5.6% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Thousand, Pricing in USD |
|
Segments Covered |
By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) |
|
Countries Covered |
Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe |
|
Market Players Covered |
Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others. |
Market Definition
Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.
Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.
Europe Adenomyosis Drugs Market Dynamics
Drivers
- High prevalence of adenomyosis disorders
Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.
With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.
- Advancement in the diagnosis of adenomyosis
The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate.
Opportunity
- Increase demand for disease-specific drug treatment
According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.
Restraints/Challenges
The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.
The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.
Recent Developments
- In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
- In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
Europe Adenomyosis Drugs Market Divide
Europe adenomyosis drugs market is categorized into six notable segments which are based on type, treatment, patient type, dosage form, distribution channel, and end user . The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Diffuse
- Nodular
- Sclerotic
- Adult cystic
- Others
On the basis of type, the Europe adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others.
Treatment
- Hormone medications
- Anti-inflammatory drugs
- Others
On the basis of treatment, the Europe adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others.
Patient Type
- Adolescence
- Adult
- Geriatric
On the basis of patient type, the Europe adenomyosis drugs market is segmented into adolescence, adult, and geriatric.
Dosage Form
- Parenteral
- Oral
- Others
On the basis of dosage form, the Europe adenomyosis drugs market is segmented into parenteral, oral, and others.
End User
- Hospitals
- Clinics
- Specialty center
- Home healthcare
- Ambulatory centers
- Others
On the basis of end user, the Europe adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers, and others.
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
On the basis of distribution channel, the Europe adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Europe Adenomyosis Drugs Market Regional Analysis/Insights
Europe adenomyosis drugs market is analyzed, and market size insights and trends are provided by type, treatment, patient type, dosage form, distribution channel, and end user, as referenced above.
The countries covered in the Europe adenomyosis drugs market report are Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe.
Germany is expected to dominate the market during the forecast period due to the rising healthcare expenditure in the country.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing a forecast analysis of the country data.
Competitive Landscape and Europe Adenomyosis Drugs Market Share Analysis
Europe adenomyosis drugs market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe adenomyosis drugs market.
Some of the key players in the market are Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe Vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ADENOMYOSIS DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR ADENOMYOSIS DRUGS MARKET
7 EUROPE ADENOMYOSIS DRUGS MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH PREVALENCE OF ADENOMYOSIS DISORDERS
8.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG
8.1.3 ADVANCEMENT IN DIAGNOSIS OF ADENOMYOSIS
8.1.4 INCREASING AWARENESS OF ADENOMYOSIS
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF ADENOMYOSIS DRUGS
8.3 OPPORTUNITIES
8.3.1 INCREASE DEMAND FOR DISEASE-SPECIFIC DRUG TREATMENT
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 ALTERNATIVE ADENOMYOSIS THERAPIES
8.4.2 IMPROPER DIAGNOSIS OF ADENOMYOSIS
9 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIFFUSE
9.2.1 BY SYMPTOMS
9.2.1.1 MENORRHAGIA
9.2.1.2 PELVIC PAIN
9.2.1.3 DYSMENORRHEA
9.2.1.4 METRORRHAGIA
9.2.1.5 OTHERS
9.2.2 BY AGE
9.2.2.1 BETWEEN 20 TO 45
9.2.2.2 ABOVE 45
9.2.2.3 BEFORE 20
9.3 NODULAR
9.3.1 BY SYMPTOMS
9.3.1.1 MENORRHAGIA
9.3.1.2 PELVIC PAIN
9.3.1.3 DYSMENORRHEA
9.3.1.4 METRORRHAGIA
9.3.1.5 OTHERS
9.3.2 BY AGE
9.3.2.1 BETWEEN 20 TO 45
9.3.2.2 ABOVE 45
9.3.2.3 BEFORE 20
9.4 SCLEROTIC
9.4.1 BY SYMPTOMS
9.4.1.1 MENORRHAGIA
9.4.1.2 PELVIC PAIN
9.4.1.3 DYSMENORRHEA
9.4.1.4 METRORRHAGIA
9.4.1.5 OTHERS
9.4.2 BY AGE
9.4.2.1 BETWEEN 20 TO 45
9.4.2.2 ABOVE 45
9.4.2.3 BEFORE 20
9.5 ADULT CYSTIC
9.5.1 BY SYMPTOMS
9.5.1.1 MENORRHAGIA
9.5.1.2 PELVIC PAIN
9.5.1.3 DYSMENORRHEA
9.5.1.4 METRORRHAGIA
9.5.1.5 OTHERS
9.5.2 BY AGE
9.5.2.1 BETWEEN 20 TO 45
9.5.2.2 ABOVE 45
9.5.2.3 BEFORE 20
9.6 OTHERS
9.6.1 ATYPICAL POLYPOID ADENOMYOMAS
9.6.1.1 BY SYMPTOMS
9.6.1.1.1 MENORRHAGIA
9.6.1.1.2 PELVIC PAIN
9.6.1.1.3 DYSMENORRHEA
9.6.1.1.4 METRORRHAGIA
9.6.1.1.5 OTHERS
9.6.1.2 BY AGE
9.6.1.2.1 BETWEEN 20 TO 45
9.6.1.2.2 ABOVE 45
9.6.1.2.3 BEFORE 20
9.6.2 JUVENILE CYSTIC ADENOMYOSIS
9.6.2.1 BY SYMPTOMS
9.6.2.1.1 MENORRHAGIA
9.6.2.1.2 PELVIC PAIN
9.6.2.1.3 DYSMENORRHEA
9.6.2.1.4 METRORRHAGIA
9.6.2.1.5 OTHERS
9.6.2.2 BY AGE
9.6.2.2.1 BETWEEN 20 TO 45
9.6.2.2.2 ABOVE 45
9.6.2.2.3 BEFORE 20
10 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 HORMONE MEDICATIONS
10.2.1 GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 NAFARELIN
10.2.1.3 GOSERELIN
10.2.1.4 OTHERS
10.2.2 ESTROGEN-PROGESTIN
10.2.2.1 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
10.2.2.3 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.4 OTHERS
10.2.3 SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN
10.2.3.1 LEVONORGESTREL
10.2.3.2 MIFEPRISTONE
10.2.3.3 ASOPRISNIL
10.2.3.4 LONAPRISAN
10.2.3.5 TELAPRISTONE ACETATE
10.2.3.6 ULIPRISTAL ACETATE
10.2.3.7 ONAPRISTONE
10.2.4 AROMATASE INHIBITORS
10.2.4.1 ARIMIDEX
10.2.4.2 FEMARA
10.2.4.3 OTHERS
10.2.5 GONADOTROPIN-RELEASING HORMONE ANTAGONIST
10.2.5.1 ELAGOLIX
10.2.5.2 FIRMAGON
10.2.5.3 OTHERS
10.2.6 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
10.2.6.1 TAMOXIFEN
10.2.6.2 RALOXIFENE
10.2.6.3 BAZEDOXIFENE
10.2.6.4 CLOMIPHENE
10.2.6.5 TOREMIFENE
10.2.6.6 OSPEMIFENE
10.2.6.7 LASOFOXIFENE
10.2.7 ANDROGEN DERIVATIVES
10.2.7.1 DANAZOL
10.2.7.2 GESTRINONE
10.3 ANTI-INFLAMMATORY DRUGS
10.3.1 NON-SELECTIVE NSAIDS
10.3.1.1 IBUPROFEN
10.3.1.2 NAPROXEN
10.3.1.3 DICLOFENAC
10.3.1.4 MEFENAMIC ACID
10.3.1.5 PIROXICAM
10.3.1.6 OTHERS
10.3.2 SELECTIVE COX-2 NSAIDS
10.3.2.1 CELECOXIB
10.3.2.2 VALDECOXIB
10.3.2.3 OTHERS
10.3.3 PREFERENTIAL COX-2 INHIBITORS
10.3.3.1 MELOXICAM
10.3.3.2 ETODOLAC
10.3.3.3 OTHERS
10.4 OTHERS
11 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 ADOLESCENCE
12 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 CAPSULES
12.2.3 SOLUTION
12.2.4 SUSPENSION
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 INTRAMUSCULAR
12.4 OTHERS
13 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 SPECIALTY CENTER
13.5 HOME HEALTHCARE
13.6 AMBULATORY CENTERS
13.7 OTHERS
14 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 EUROPE ADENOMYOSIS DRUGS MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 U.K.
15.1.3 FRANCE
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 RUSSIA
15.1.7 NETHERLANDS
15.1.8 SWITZERLAND
15.1.9 POLAND
15.1.10 TURKEY
15.1.11 HUNGARY
15.1.12 AUSTRIA
15.1.13 NORWAY
15.1.14 IRELAND
15.1.15 LITHUANIA
15.1.16 REST OF EUROPE
16 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.1.5.1 ACQUISITION
18.1.5.2 PARTNERSHIP
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.2.5.1 MERGER
18.3 SANOFI
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.3.5.1 MERGER
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.4.5.1 PARTNERSHIP
18.5 BAYER AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.5.5.1 ACQUISITION
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 PRODUCT APPROVAL
18.7 ACCORD HEALTHCARE
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 AMNEAL PHARMACEUTICALS LLC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.8.4.1 EVENT
18.9 ASTRAZENECA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.9.4.1 EXPANSION
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CONTEXT THERAPEUTICS INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.11.3.1 EVENT
18.12 DR. REDDY’S LABORATORIES LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.12.4.1 ACQUISITION
18.13 FERRING B.V.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.13.3.1 COLLABORATION
18.14 GLAXOSMITHKLINE PLC
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.14.4.1 PARTNERSHIP
18.15 HIKMA PHARMACEUTICALS PLC
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 JOHNSON & JOHNSON SERVICES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.16.4.1 EVENT
18.17 LANNETT
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.17.4.1 EVENT
18.18 MAYNE PHARMA GROUP LIMITED
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.18.4.1 PRODUCT LAUNCH
18.19 NOVARTIS AG
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.19.4.1 PRODUCT DEVELOPMENT
18.19.4.2 ACQUISITION
18.2 PAR PHARMACEUTICAL ( A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 SUN PHARMACEUTICAL INDUSTRIES LTD
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 TERSERA THERAPEUTICS LLC
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.22.3.1 AGREEMENT
18.23 TOLMAR PHARMACEUTICALS, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.23.3.1 PRODUCT LAUNCH
18.23.3.2 EXPANSION
18.24 VIATRIS INC
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.24.4.1 AGREEMENT
18.25 ZYDUS PHARMACEUTICALS, INC.
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.25.3.1 ACQUISITION
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
TABLE 1 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 2 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 4 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 5 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 7 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 8 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 10 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 11 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 12 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 13 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 14 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 16 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 17 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 18 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 19 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 20 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 21 EUROPE HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 22 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 23 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 24 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 25 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 26 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 27 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 28 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 29 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 30 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 32 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 33 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 34 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 35 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 37 EUROPE ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 EUROPE GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 EUROPE ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 41 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 43 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 45 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 46 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 47 EUROPE HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 EUROPE CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 49 EUROPE SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 EUROPE HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 EUROPE AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 52 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 53 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 54 EUROPE HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 55 EUROPE RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 56 EUROPE ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 57 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 58 EUROPE ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 59 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 60 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 61 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 62 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 63 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 64 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 65 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 66 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 67 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 68 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 70 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 71 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 72 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 73 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 75 EUROPE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 76 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 77 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 78 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 79 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 80 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 81 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 82 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 83 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 84 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 87 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 88 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 89 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 90 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 92 GERMANY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 93 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 94 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 95 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 96 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 97 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 98 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 99 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 100 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 101 GERMANY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 102 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 103 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 104 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 105 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 106 GERMANY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 GERMANY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 GERMANY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 GERMANY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 GERMANY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 GERMANY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 GERMANY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 GERMANY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 115 GERMANY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 116 GERMANY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 117 GERMANY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 118 GERMANY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 119 GERMANY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 120 GERMANY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 GERMANY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 GERMANY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 GERMANY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 124 GERMANY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 125 U.K. ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 127 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 128 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 129 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 130 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 131 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 132 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 133 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 134 U.K. OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 135 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 136 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 137 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 138 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 139 U.K. ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 140 U.K. HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 141 U.K. GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 142 U.K. ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 143 U.K. SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 144 U.K. AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 145 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 146 U.K. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 147 U.K. ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 148 U.K. ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 149 U.K. NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 150 U.K. SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 151 U.K. PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 152 U.K. ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 153 U.K. ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 154 U.K. ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 155 U.K. PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 156 U.K. ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 157 U.K. ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 158 FRANCE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 159 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 160 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 161 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 162 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 163 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 164 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 165 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 166 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 167 FRANCE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 168 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 169 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 170 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 171 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 172 FRANCE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 173 FRANCE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 174 FRANCE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 175 FRANCE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 176 FRANCE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 177 FRANCE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 178 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 179 FRANCE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 180 FRANCE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 181 FRANCE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 182 FRANCE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 183 FRANCE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 184 FRANCE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 185 FRANCE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 186 FRANCE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 187 FRANCE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 188 FRANCE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 189 FRANCE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 190 FRANCE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 191 ITALY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 192 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 193 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 194 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 195 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 196 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 197 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 198 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 199 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 200 ITALY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 201 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 202 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 203 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 204 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 205 ITALY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 206 ITALY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 207 ITALY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 208 ITALY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 209 ITALY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 210 ITALY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 211 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 212 ITALY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 213 ITALY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 214 ITALY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 215 ITALY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 216 ITALY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 217 ITALY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 218 ITALY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 219 ITALY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 220 ITALY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 221 ITALY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 222 ITALY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 223 ITALY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 224 SPAIN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 225 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 226 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 227 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 228 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 229 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 230 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 231 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 232 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 233 SPAIN OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 234 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 235 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 236 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 237 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 238 SPAIN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 239 SPAIN HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 240 SPAIN GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 241 SPAIN ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 242 SPAIN SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 243 SPAIN AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 244 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 245 SPAIN SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 246 SPAIN ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 247 SPAIN ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 248 SPAIN NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 249 SPAIN SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 250 SPAIN PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 251 SPAIN ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 252 SPAIN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 253 SPAIN ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 254 SPAIN PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 255 SPAIN ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 256 SPAIN ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 257 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 258 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 259 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 260 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 261 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 262 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 263 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 264 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 265 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 266 RUSSIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 267 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 268 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 269 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 270 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 271 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 272 RUSSIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 273 RUSSIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 274 RUSSIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 275 RUSSIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 276 RUSSIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 278 RUSSIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 279 RUSSIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 280 RUSSIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 281 RUSSIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 282 RUSSIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 283 RUSSIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 284 RUSSIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 285 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 286 RUSSIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 287 RUSSIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 288 RUSSIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 289 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 290 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 291 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 292 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 293 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 294 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 295 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 296 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 297 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 298 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 299 NETHERLANDS OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 300 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 301 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 302 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 303 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 304 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 305 NETHERLANDS HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 306 NETHERLANDS GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 307 NETHERLANDS ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 308 NETHERLANDS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 309 NETHERLANDS AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 310 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 311 NETHERLANDS SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 312 NETHERLANDS ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 313 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 314 NETHERLANDS NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 315 NETHERLANDS SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 316 NETHERLANDS PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 317 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 318 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 319 NETHERLANDS ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 320 NETHERLANDS PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 321 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 322 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 323 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 324 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 325 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 326 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 327 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 328 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 329 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 330 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 331 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 332 SWITZERLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 333 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 334 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 335 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 336 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 337 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 338 SWITZERLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 339 SWITZERLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 340 SWITZERLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 341 SWITZERLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 342 SWITZERLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 343 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 344 SWITZERLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 345 SWITZERLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 346 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 347 SWITZERLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 348 SWITZERLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 349 SWITZERLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 350 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 351 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 352 SWITZERLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 353 SWITZERLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 354 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 355 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 356 POLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 357 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 358 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 359 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 360 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 361 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 362 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 363 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 364 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 365 POLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 366 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 367 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 368 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 369 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 370 POLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 371 POLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 372 POLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 373 POLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 374 POLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 375 POLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 376 POLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 377 POLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 378 POLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 379 POLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 380 POLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 381 POLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 382 POLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 383 POLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 384 POLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 385 POLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 386 POLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 387 POLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 388 POLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 389 TURKEY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 390 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 391 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 392 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 393 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 394 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 395 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 396 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 397 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 398 TURKEY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 399 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 400 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 401 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 402 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 403 TURKEY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 404 TURKEY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 405 TURKEY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 406 TURKEY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 407 TURKEY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 408 TURKEY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 409 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 410 TURKEY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 411 TURKEY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 412 TURKEY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 413 TURKEY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 414 TURKEY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 415 TURKEY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 416 TURKEY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 417 TURKEY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 418 TURKEY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 419 TURKEY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 420 TURKEY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 421 TURKEY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 422 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 423 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 424 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 425 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 426 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 427 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 428 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 429 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 430 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 431 HUNGARY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 432 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 433 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 434 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 435 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 436 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 437 HUNGARY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 438 HUNGARY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 439 HUNGARY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 440 HUNGARY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 441 HUNGARY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 442 UNGARY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 443 HUNGARY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 444 HUNGARY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 445 HUNGARY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 446 HUNGARY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 447 HUNGARY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 448 HUNGARY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 449 HUNGARY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 450 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 451 HUNGARY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 452 HUNGARY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 453 HUNGARY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 454 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 455 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 456 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 457 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 458 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 459 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 460 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 461 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 462 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 463 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 464 AUSTRIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 465 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 466 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 467 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 468 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 469 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 470 AUSTRIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 471 AUSTRIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 472 AUSTRIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 473 AUSTRIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 474 AUSTRIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 475 AUSTRIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 476 AUSTRIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 477 AUSTRIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 478 AUSTRIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 479 AUSTRIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 480 AUSTRIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 481 AUSTRIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 482 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 483 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 484 AUSTRIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 485 AUSTRIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 486 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 487 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 488 NORWAY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 489 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 490 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 491 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 492 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 493 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 494 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 495 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 496 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 497 NORWAY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 498 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 499 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 500 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 501 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 502 NORWAY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 503 NORWAY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 504 NORWAY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 505 NORWAY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 506 NORWAY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 507 NORWAY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 508 NORWAY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 509 NORWAY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 510 NORWAY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 511 NORWAY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 512 NORWAY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 513 NORWAY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 514 NORWAY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 515 NORWAY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 516 NORWAY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 517 NORWAY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 518 NORWAY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 519 NORWAY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 520 NORWAY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 521 IRELAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 522 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 523 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 524 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 525 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 526 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 527 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 528 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 529 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 530 IRELAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 531 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 532 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 533 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 534 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 535 IRELAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 536 IRELAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 537 IRELAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 538 IRELAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 539 IRELAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 540 IRELAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 541 IRELAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 542 IRELAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 543 IRELAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 544 IRELAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 545 IRELAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 546 IRELAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 547 IRELAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 548 IRELAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 549 IRELAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 550 IRELAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 551 IRELAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 552 IRELAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 553 IRELAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 554 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 555 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 556 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 557 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 558 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 559 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 560 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 561 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 562 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 563 LITHUANIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 564 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 565 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 566 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 567 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 568 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 569 LITHUANIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 570 LITHUANIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 571 LITHUANIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 572 LITHUANIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 573 LITHUANIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 574 LITHUANIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 575 LITHUANIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 576 LITHUANIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 577 LITHUANIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 578 LITHUANIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 579 LITHUANIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 580 LITHUANIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 581 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 582 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 583 LITHUANIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 584 LITHUANIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 585 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 586 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 587 REST OF EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
Lista de figuras
FIGURE 1 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE ADENOMYOSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ADENOMYOSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ADENOMYOSIS DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ADENOMYOSIS DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE ADENOMYOSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE ADENOMYOSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE ADENOMYOSIS DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE ADENOMYOSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 HIGH PREVALENCE OF ADENOMYOSIS DISORDER AND INCREASE THE RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG ARE DRIVING THE EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DIFFUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADENOMYOSIS DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ADENOMYOSIS DRUGS MARKET
FIGURE 16 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 17 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 18 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2021
FIGURE 21 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2022-2029 (USD THOUSAND)
FIGURE 22 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, LIFELINE CURVE
FIGURE 24 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2021
FIGURE 25 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 26 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 28 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 30 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2021
FIGURE 33 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 34 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 35 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 38 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 EUROPE ADENOMYOSIS DRUGS MARKET : SNAPSHOT (2021)
FIGURE 41 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021)
FIGURE 42 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 43 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 44 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 45 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
